CytomX Therapeutics, Inc. (CTMX)
CTMX moved a median of 0.00% 30 minutes after news, and -0.48% by the close. How CTMX actually reacts to news — the realized, point-in-time move the market made, measured across 267 labeled events over the last three years with zero look-ahead.
CTMX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 266 |
| 30-min | 0.00% | 44% | 267 |
| 60-min | -0.38% | 47% | 267 |
| to close | -0.48% | 45% | 264 |
| Middle 50% of CTMX reactions | -2.70% to +1.48% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 267 |
Half of all CytomX Therapeutics, Inc. news events land between -2.70% and +1.48% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CTMX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 29 | -2.68% | 17% | -6.77% |
| Coverage initiations | 16 | -0.23% | 31% | -0.52% |
| Rating reiterations | 52 | -1.18% | 35% | -3.07% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CTMX ranks against every other measured name →
That’s how CTMX usually reacts — get an email when it moves on news →Email me when CTMX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CTMX's baseline. Nothing else.
Recent CTMX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| CytomX Therapeutics to Present at Upcoming September Investor Conferences | Press release | GlobeNewswire | +1.96% | +10.54% | |
| CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | Press release | GlobeNewswire | -1.02% | -0.29% | |
| CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.60% | +4.22% | |
| Form 10-Q CytomX Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.60% | +4.22% | |
| Form 8-K CytomX Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.60% | +4.22% | |
| Form S-8 CytomX Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.60% | +4.22% | |
| CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer | Press release | GlobeNewswire | -1.94% | +2.59% | |
| CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | GlobeNewswire | +1.10% | +3.15% | |
| CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors | Press release | GlobeNewswire | +1.23% | +0.00% | |
| Form 8-K CytomX Therapeutics, For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | +1.23% | +0.00% | |
| A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs | Press release | Canada Newswire | -0.26% | -0.26% | |
| Form 8-K CytomX Therapeutics, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +0.66% | +3.62% | |
| CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | Press release | GlobeNewswire | -0.35% | +0.63% | |
| Form 8-K CytomX Therapeutics, For: May 29 | SEC filing · Form 8-K | SEC EDGAR | +0.15% | -1.55% | |
| CytomX Therapeutics to Present at Upcoming June Investor Conferences | Press release | GlobeNewswire | -0.27% | +1.90% | |
| CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs | Press release | GlobeNewswire | -0.69% | -2.78% | |
| CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.98% | -1.49% | |
| Form 10-Q CytomX Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.98% | -1.49% | |
| Form 8-K CytomX Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +1.98% | -1.49% | |
| CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | GlobeNewswire | -0.24% | +3.18% | |
| Form DEF 14A CytomX Therapeutics, For: Jun 17 | SEC filing · Form DEF | SEC EDGAR | +1.30% | -0.95% | |
| Form DEFA14A CytomX Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +1.30% | -0.95% | |
| Form PRE 14A CytomX Therapeutics, For: Jun 17 | SEC filing · Form PRE | SEC EDGAR | +1.43% | -2.66% | |
| Form 8-K CytomX Therapeutics, For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -0.88% | -3.26% | |
| CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -3.77% | -16.98% | |
| CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -6.20% | -2.74% | |
| CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -2.60% | -21.13% | |
| CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer | Press release | GlobeNewswire | -6.20% | -2.74% | |
| Form 10-K CytomX Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -6.20% | -2.74% | |
| Form 8-K CytomX Therapeutics, For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | -6.20% | -2.74% | |
| Form S-3ASR CytomX Therapeutics, | SEC filing · Form S-3ASR | SEC EDGAR | -2.60% | -21.13% | |
| CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 | Press release | GlobeNewswire | +0.10% | +4.32% | |
| CytomX Therapeutics to Present at Upcoming February Conferences | Press release | GlobeNewswire | -0.16% | -8.40% | |
| CytomX Therapeutics Announces Business Update and Company Milestones for 2026 | Press release | GlobeNewswire | +0.23% | -1.62% | |
| CytomX Therapeutics to Present at Upcoming December Investor Conferences | Press release | GlobeNewswire | +1.27% | +5.06% | |
| CytomX Therapeutics to Present at the Jefferies London Healthcare Conference | Press release | GlobeNewswire | -2.47% | — | |
| CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -4.74% | -4.74% | |
| Form 10-Q CytomX Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.74% | -4.74% | |
| Form 8-K CytomX Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -4.74% | -4.74% | |
| CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting | Press release | GlobeNewswire | +1.84% | +7.63% | |
| CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 | Press release | GlobeNewswire | -0.77% | +2.46% | |
| CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer | Press release | GlobeNewswire | -3.33% | -7.31% | |
| CytomX Therapeutics to Present at Upcoming September Investor Conferences | Press release | GlobeNewswire | +1.91% | -1.91% | |
| Form EFFECT CytomX Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -0.71% | — | |
| CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study | Press release | GlobeNewswire | +2.10% | -6.58% | |
| Form 8-K CytomX Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +2.10% | -6.58% | |
| CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +2.93% | +14.63% | |
| Form 10-Q CytomX Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.93% | +14.63% | |
| Form 8-K CytomX Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +2.93% | +14.63% | |
| Form S-3 CytomX Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +2.93% | +14.63% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CTMX section they belong to.
Where else CTMX is measured.
CTMX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CONMED Corporation (CNMD) | 268 | -0.11% | 47% |
| Codexis, Inc. (CDXS) | 267 | 0.00% | 51% |
| Galapagos NV - American Depositary Shares (GLPG) | 267 | -0.05% | 44% |
| Eyenovia, Inc. (EYEN) | 266 | -0.95% | 38% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CytomX Therapeutics, Inc.'s median reaction calculated?
Every labeled CTMX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 267 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of CTMX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CTMX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.